GSC
RXRX icon

Ground Swell Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Ground Swell Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,553
Closed -$77K – 246
2025
Q1 		$77K Buy
+14,553
New +$106K 0.17% 118

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Ground Swell Capital's RXRX Position: Q2 2025 in Review

Ground Swell Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 14,553 shares — an estimated $77K sold.

Ground Swell Capital first reported a position in RXRX in Q1 2025 and held it in 1 quarter. The position peaked at $77K in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Ground Swell Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ground Swell Capital sold 14,553 Recursion Pharmaceuticals shares in Q2 2025, an estimated $77K.
  • Ground Swell Capital first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Ground Swell Capital's Recursion Pharmaceuticals position peaked at $77K in Q1 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Ground Swell Capital's 13F filing for Q2 2025, filed 31 Jul 2025.